What to Expect:
The consensus estimate is $1.36 per share, up 0.7% from a year ago when Johnson & Johnson reported earnings of $1.35 per share. Over the past three months, the consensus estimate has increased from $1.33. For the fiscal year, analysts are projecting earnings of $5.10 per share.
Revenue is projected to be $16.27 billion for the quarter, 0.6% above the year-earlier total of $16.17 billion. For the year, revenue is expected to come in at $66.4 billion.
Trends to Watch For:
Analyst Ratings:
The majority of analysts (52.2%) rate Johnson & Johnson as a buy. This compares favorably to the analyst ratings of its nearest 10 competitors, which average 50.6% buys. Analysts have grown increasingly optimistic about the stock in the last three months.
Competitors:
Johnson & Johnson is engaged in the research and development, manufacture, and sale of a range of products in the health care field. One of Johnson & Johnson’s main competitors in the pharmaceuticals industry, Pfizer (PFE), will report earnings on May 1, 2012. Other competitors in the healthcare sector include: Merck & Co (MRK), Abbott Laboratories Com Stk NPV (ABT), and Eli Lilly & Co (LLY).
Recent Price Movement:
The stock price has fallen slightly over the past quarter, from $64.69 on January 13, 2012 to its current price, $64.13.
Earnings estimates provided by Zacks.
For the latest updates on the stock market, PRESS CTR + D or visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today
No comments:
Post a Comment